The EME commissioned workstream is funded by the NIHR with contributions from the CSO in Scotland and NISCHR in Wales and the HSC R&D, Public Health Agency in Northern Ireland.
The EME commissioned workstream will fund large, often staged, projects which are of benefit to patients and the NHS. Proposals may include pilot and feasibility studies and late development of technologies.
Proposals are expected to be in the form of a substantial collaboration with at least two of the following three partners: industry, NHS and academia.
The remit of the EME commissioned workstream includes clinical trials and evaluative studies, in patients, which:
- evaluate clinical efficacy of interventions;
- add significantly to our understanding of biological or behavioural mechanisms and processes;
- explore new scientific or clinical principles;
- include the development or testing of new methodologies.
The EME commissioned workstream WILL support:
- research which seeks to determine definitive proof of clinical efficacy and size of effect, safety and possibly effectiveness;
- studies that use validated surrogate markers as indicators of health outcome;
- laboratory based, or similar, studies that are embedded within the main study, if relevant to the remit of the EME programme.
The EME commissioned workstream WILL NOT support:
- confirmatory studies or trials of incremental modifications and refinements to existing medical interventions;
- 'confidence in effect' studies;
- research into 'global health', where 'global health' can be defined as 'areas where the health need is identified in developing countries (i.e. including diseases of developing countries), or where the health need does not yet exist in the UK but might in the future and the problem can be best addressed in developing countries';
- research involving animals.
The EME commissioned workstream will support research proposals which are important to healthcare, from researchers based across the UK (England, Scotland, Wales and Northern Ireland).
|